Skip to main content

Table 1 Baseline demographic and clinical characteristics of the patients

From: A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

Variable Groups P value
Control (N = 33) Intervention (N = 34)
Gender (N; male/female) 9/24 13/21 0.44
Age (years; mean ± SD) 43.45 ± 10.35 44.41 ± 11.25 0.95
BMI (Kg/m2; mean ± SD) 22.71 ± 3.19 22.27 ± 2.95 0.57
IBS duration (Years; mean ± SD) 9.2 ± 7.74 10.0 ± 6.52 0.65
  1. BMI Body mass index, IBS Irritable bowel syndrome